Taglich Brothers reaffirmed their speculative buy rating on shares of Zynex Inc. (OTC:ZYXI) in a research report sent to investors on Monday morning. Taglich Brothers also issued estimates for Zynex’s Q3 2017 earnings at $0.06 EPS, Q4 2017 earnings at $0.02 EPS, Q1 2018 earnings at $0.02 EPS, Q2 2018 earnings at $0.07 EPS, Q3 2018 earnings at $0.07 EPS, Q4 2018 earnings at $0.03 EPS and FY2018 earnings at $0.19 EPS.
Zynex (OTC:ZYXI) opened at 1.29 on Monday. The stock has a 50 day moving average of $0.85 and a 200 day moving average of $0.49. Zynex has a 12-month low of $0.10 and a 12-month high of $1.68. The company has a market cap of $41.34 million and a PE ratio of 15.73.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://stocknewstimes.com/2017/08/24/zynexs-zyxi-speculative-buy-rating-reiterated-at-taglich-brothers.html.
About Zynex
Zynex, Inc operates through the Electrotherapy and Pain Management Products segment. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc (ZMI). Its other subsidiaries include Zynex Monitoring Solutions, Inc (ZMS) and Zynex Europe, ApS (ZEU). ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation.
Receive News & Ratings for Zynex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
